Louvain-la-Neuve, Belgium--(BUSINESS WIRE)--IBA (Ion Beam Applications S.A.) announced that it has signed a contract with Seattle Procure Management LLC for the installation of a proton therapy system in Seattle, WA (USA).

The proton therapy center will be owned and operated in partnership with the Seattle Cancer Care Alliance and will be built on the campus of Northwest Hospital & Medical Center in North Seattle. It will include a combination of gantry (isocentric rotating frames), inclined beam and fixed beam rooms - with the latest options for patient positioning and the IBA Universal Nozzle technology, including the latest Pencil Beam Scanning technology. The partnership will also include a long-term service and maintenance agreement.

This contract totals about 45 to 55 million Euros. The final contract is still subject to financing and usual administrative formalities. The company does not expect significant financial impact on FY 2010.

"We are very pleased to be developing another proton center with ProCure," said Pierre Mottet, IBA's Chief Executive Officer. "ProCure has developed a unique concept to make proton therapy available to hospitals and radiation oncologists on a fully integrated turn-key basis which has proved to be very attractive to the market."

“We are delighted to work once more with IBA on another proton therapy center,” said Hadley Ford, ProCure's Chief Executive Officer. “IBA’s unique experience and leading edge solution allow us to deploy this very advanced technology much faster and more comfortably than with any of their competitors.”

IBA is committed to making proton therapy - the most accurate cancer treatment - available worldwide. Up to now, IBA has sold 17 proton therapy centers, which represents more than half of the clinical-based proton therapy facilities in the world.

Proton therapy is increasingly considered the best radiotherapy for cancer due to its superior dose distribution. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, and, even better, spare healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, improving outcome and quality of life for patients. Unfortunately, very few patients can yet benefit from this type of treatment around the world.

ABOUT PROCURE TREATMENT CENTERS, INC.
ProCure Treatment Centers, Inc., based in Bloomington, IN, was founded in 2005 aiming to improve the lives of cancer patients by increasing access to proton therapy. ProCure collaborates with leading radiation oncology practices and hospitals and provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training and day-to-day operations of world-class proton therapy centers. ProCure's solution reduces the time, cost and effort required to open a facility. ProCure is the only company in the world with one center already open and treating patients (Oklahoma City, OK), another under construction, and scheduled to open in the Fall of 2010, in suburban Chicago (Warrenville), and four others under development (Seattle, WA; Somerset, NJ; South Florida; FL and Detroit, MI). ProCure's Training and Development Center is the first facility in the world dedicated exclusively to proton therapy. For more information, visit www.procure.com.

ABOUT IBA
IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: www.iba-worldwide.com